- Home
- CCAP vs VSTM Comparison
CCAP vs VSTM Comparison
Compare CCAP & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCAP | VSTM |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.4M | 470.7M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | CCAP | VSTM |
|---|---|---|
| Price | $12.88 | $6.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $16.33 | $14.50 |
| AVG Volume (30 Days) | 187.3K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 12.94% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $201.42 |
| Revenue Next Year | N/A | $263.25 |
| P/E Ratio | $14.18 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $12.56 | $4.01 |
| 52 Week High | $17.97 | $11.25 |
Technical Indicators
Market Signals| Indicator | CCAP | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 52.97 |
| Support Level | $12.56 | $5.56 |
| Resistance Level | $14.70 | $6.91 |
| Average True Range (ATR) | 0.45 | 0.33 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 21.09 | 76.47 |
Price Performance
Historical ComparisonAbout CCAP Crescent Capital BDC Inc.
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.